Search Results

Sonoma Pharmaceuticals, Inc. today announced the launch of its MicrocynAH animal health care products in the Menards chain of home improvement stores in the United States.

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2024 and the fourth quarter ended March 31, 2024.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced that it will be presenting at two upcoming investor conferences in Denver and New York.

NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova branded products by Sonoma in the European Union.

Sonoma Pharmaceuticals, Inc. today announced the expansion of its Microcyn Negative-Pressure Wound Therapy (NPWT) Solution products in the United States.

Sonoma Pharmaceuticals, Inc. reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for Microdox in the management of urinary tract infections.

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) today announced financial results for its third fiscal quarter and nine months ended December 31, 2023.

Sonoma Pharmaceuticals, Inc. today announced the pricing of its public offering of 8,500,000 shares of common stock at a price of $0.20 per share.